Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.
- Solara Active Pharma reported Total revenue for Q4 FY23 of ₹381 Crore, up from ₹361 Crore year on year depicting a growth of 6%.
- Total Expenses for Q4 FY23 of ₹332 Crore down, from ₹347 Crore year on year, a decline of 4%.
- Consolidated Net Profit of ₹3.76 Crore, up 108% from ₹1.81 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹1.05, up 102% from ₹0.52 in the same quarter of the previous year.